Abstract:A series of novel hybrid pyrazolo[3,4-d]pyramidine derivatives was designed and chemically synthesized in useful yields. The synthesized compounds were structurally characterized by the usual techniques. All the new synthesized compounds were biologically screened in vitro for their antiproliferative activities against a panel of four cancer cell lines, namely HepG-2, MCF-7, HCT-116, and Hela. The results of cytotoxic evaluation indicated that compound 14d was appeared to be the most prominent broad-spectrum cytotoxic activity and significantly more potent than sorafenib with IC50 values of 4.28, 5.18, 3.97, and 9.85 µM against four cell lines (HePG2, Hela, HCT-116 and MCF-7). In addition, compound 15 was displayed promising antiproliferative effect against all tested cell lines with IC50 value less than 11 µM compared with sorafenib as a control drug. Besides, structurally pharmacophoric features indicated that pyrazolo[3,4-d]pyrimidine scaffold having an amide linker and substituted with phenyl moiety at the 5-position was more potent than those possessing azomethine methyl, azomethine proton and carbomethene linkers, which lead to significant decrease in antiproliferative activity. The most potent compounds were further selected and evaluated for their activities against epidermal growth factor receptor (EGFR) kinase inhibitors according to homogenous time resolved fluorescence (HTRF) assay. The most potent compound 14d exhibited the most promising inhibitory activity against EGFRWT with IC50 value of 56.02 ± 1.38 µM compared with gefitinib as control drug with IC50 value of 41.79 ± 1.07 µM. Moreover, the inhibition of cell cycle progression and induction of apoptosis in the A549 cell line at G2/M and pre-G1 phases of cell cycle might contribute to cancer treatment that evaluated by Annexin V-FITC/PI double staining detection method. Finally, molecular docking studies were conducted to investigate that probable binding conformations of these anticancer agents and ADME properties were calculated to predict pharmacokinetics and toxic properties of the target compounds.

Synthesis and Biological Evaluation of 4-[3-chloro-4-(3-fluorobenzyloxy) Anilino]-6-(3-Substituted-Phenoxy)Pyrimidines As Dual Egfr/Erbb-2 Kinase Inhibitors

Design, Synthesis, Anti-Tumor Activity, and Molecular Modeling of Quinazoline and Pyrido[2,3-D]Pyrimidine Derivatives Targeting Epidermal Growth Factor Receptor

Synthesis, Characterization and Biological Activity of Tetrahydrobenzo[4,5]thieno[2,3-D]pyrimidine Derivatives As Epidermal Growth Factor Receptor Inhibitors

Synthesis, Molecular Docking and Evaluation of Thiazolyl-Pyrazoline Derivatives As Egfr Tk Inhibitors and Potential Anticancer Agents

Optimization of Substituted 6-Salicyl-4-anilinoquinazoline Derivatives As Dual Egfr/Her2 Tyrosine Kinase Inhibitors

Design, Synthesis, Biological Evaluation and Molecular Modeling of Novel 1H-Pyrazolo[3,4-d]pyrimidine Derivatives As BRAF(V600E) and VEGFR-2 Dual Inhibitors

Design, Synthesis and Biological Evaluation of Novel 6-Alkenylamides Substituted of 4-Anilinothieno[2,3-d]pyrimidines As Irreversible Epidermal Growth Factor Receptor Inhibitors.

Design, synthesis and biological evaluation of aminopyrimidine derivatives bearing a 4,5,6,7-tetrahydrothieno [3,2-c]pyridine as potent EGFR inhibitors

The Synthesis and Bioactivity of Pyrrolo[2,3-D]pyrimidine Derivatives As Tyrosine Kinase Inhibitors for NSCLC Cells with EGFR Mutations.

Synthesis, biological evaluation and molecular docking studies of new pyrimidine derivatives as potent dual EGFR/HDAC inhibitors

Design, Synthesis and Biological Evaluation of Novel 4-Anilinoquinazolines with C-6 Urea-Linked Side Chains As Inhibitors of the Epidermal Growth Factor Receptor.

Design, Synthesis and Pharmacological Evaluation of N4,N6-disubstituted Pyrimidine-4,6-diamine Derivatives As Potent EGFR Inhibitors in Non-Small Cell Lung Cancer

Synthesis, Characterization, Screening And Docking Analysis Of 4-Anilinoquinazoline Derivatives As Tyrosine Kinase Inhibitors

Design, synthesis and anticancer evaluation of new 4-anilinoquinoline-3-carbonitrile derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers

Design, synthesis and evaluation of new pyrimidine derivatives as EGFRC797S tyrosine kinase inhibitors

Discovery of thiapyran-pyrimidine derivatives as potential EGFR inhibitors

Design, synthesis and molecular docking of new fused 1H-pyrroles, pyrrolo[3,2-d]pyrimidines and pyrrolo[3,2-e][1, 4]diazepine derivatives as potent EGFR/CDK2 inhibitors

Design, synthesis and biological evaluation of pyrazolyl-nitroimidazole derivatives as potential EGFR/HER-2 kinase inhibitors

Design, Synthesis, biological Evaluation, and molecular docking studies of novel Pyrazolo[3,4-d]Pyrimidine derivative scaffolds as potent EGFR inhibitors and cell apoptosis inducers

Design, synthesis, and biological evaluation of 2-arylamino-4-(piperidin-4-yloxy)pyrimidines as potent EGFRT790M/L858R inhibitors to treat non-small cell lung cancer

Design, synthesis and antitumor activity of 4-indazolylpyrimidine derivatives as EGFR inhibitors